Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation

• US 7,256,287 B2
• Filed: 09/12/2003
• Issued: 08/14/2007
• Est. Priority Date: 09/12/2002
• Status: Expired due to Fees

• Current Assignee: Avanir Pharmaceuticals (Otsuka Holdings Company Limited)
• Original Assignee: Avanir Pharmaceuticals (Otsuka Holdings Company Limited)
• Inventors: Sinha, Anjana, Sircar, Jagadish C., Richards, Mark L., Thomas, Richard J.
• Primary Examiner(s): Seaman; Margaret D.
• Assistant Examiner(s): Rahmani; Niloofar
• Application Number:
  US10/661,296
• Publication Number:
  US 20040116466A1
• Time in Patent Office: 1,432 Days
• Field of Search: 546/118, 544/235, 544/253, 544/349, 544/179, 544/180
• US Class Current: 544/235
• CPC Class Codes: A61K 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to phenyl-aza-benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. This invention further relates to small molecules which suppress cytokines and leukocytes.

Claims

1. A compound or salt thereof represented by one or more of the following formulas:

2. The compound or salt thereof of claim 1, wherein the Supragenus A-D are represented by the formulas:

3. The compound or salt thereof of claim 1, wherein said polycyclic aliphatic group is selected from the group consisting of adamantyl, bicycloheptyl, camphoryl, bicyclo[2,2,2]octanyl and norbornyl.

4. The compound or salt thereof of claim 1, wherein said heteroaryl and said substituted heteroaryl is selected from the group consisting of pyridines, thiazoles, isothiazoles, oxazoles, pyrimidines, pyrazines, furans, thiophenes, isoxazoles, pyrroles, pyridazines, 1,2,3-triazines, 1,2,4-triazines, 1,3,5-triazines, pyrazoles, imidazoles, indoles, quinolines, iso-quinolines, benzothiophines, benzofurans, parathiazines, pyrans and chromenes.

5. The compound or salt thereof of claim 1, wherein R₁ and R₂ are independently selected from the group consisting of:

6. The compound or salt thereof of claim 1 selected from the group consisting of:

7. A compound or salt thereof represented by the following formula:

8. The compound or salt thereof of claim 7 selected from the group consisting of:

9. The compound or salt thereof of claim 8 represented by the formula:

10. A compound or salt thereof represented by the following formula:

11. The compound or salt thereof of claim 10 selected from the group consisting of:

12. A compound or salt thereof represented by the following formula:

13. The compound or salt thereof of claim 12 represented by the formula:

14. A compound or salt thereof represented by the following formula:

15. The compound or salt thereof of claim 14 represented by the formula:

16. A compound or salt thereof represented by the following formula:

17. A compound or salt thereof represented by the following formula: